Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin

Lashin, Amany; Shaheen, Yasser; Metwally, Mohamed A.; Elfeky, Hala M.; Hegab, Mohsen; Abbas, Sarwar

doi:10.1007/s12664-013-0336-z

Cited by 8 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was significant difference between the measured hemoglobin level before and after treatment in Triple group, these agreements with a study in Shebein EL-Kom Teaching Hospital, Hepatology Department as a part of the Egyption Ministry of Health project for the treatment of hepatitis C virus (Lashin et al, 2013) where decrease in hemoglobin in 28.8% of the Triple group. the Platelet count ×1000mm³ decrease from 217.55 ± 87.85(cells\mcL) to 197.00 ±71.46 (cells/mcL) in the Dual treatment regimen, while in the Triple treatment regimen, the Platelet count ×1000mm³ decreased from 210.62 ±64.63to 171.10 ± 67.59 (cells/mcL).…”

Section: N=number Sd=standard Deviationsupporting

confidence: 87%

تقييم الحالة الغذائية لمرضى الالتهاب الکبدي سي بمستشفى کبد المحلة التعليمي

الشافعى¹,

رزق²,

بدر³

2020

مجلة الاقتصاد المنزلي.جامعة المنوفية

View full text Add to dashboard Cite

Malnutrition is prevalent among patients with chronic liver disease. Therefore, the aim of this work is to assess the nutritional status of patients with Hepatitis C virus and based therapy of sofosbuvir. Patients were compared with the different methods which used for nutritional assessment namely the anthropometric measures and the Subjective Global Assessment (SGA). Patients and Methods: This study was conducted in Mahalla Hepatology Teaching Hospital in order to assess the nutritional status of 68 chronic hepatitis C patients receiving triple antiviral regimen that consisted of (Sofosbuvir (Sovaldi) + Daklinza + Ribavirin) that were administered orally for 3 months and dual antiviral regimen that consisted of Sofosbuvir (Sovaldi) + Daklinza) that are administerd orally for 3 months with 40 chronic hepatitis C patients per group. Thorough history taking, physical examination and detailed nutritional assessment were performed including a 24-hour dietary recall. Evaluation of nutritional status was done using different anthropometric measures and the Subjective Global Assessment (SGA). Nutritional assessment based on Comparison of dual therapy with triple therapy laboratory findings of those patients that reflect their nutritional status as hemoglobin, liver enzymes (AST, ALT), total bilirubin, ultra sound, WBCs count and platelets count before treatment and after

show abstract

Section: N=number Sd=standard Deviationsupporting

confidence: 87%

تقييم الحالة الغذائية لمرضى الالتهاب الکبدي سي بمستشفى کبد المحلة التعليمي

الشافعى¹,

رزق²,

بدر³

2020

مجلة الاقتصاد المنزلي.جامعة المنوفية

View full text Add to dashboard Cite

show abstract

“…In our cohort, 77.3% of patients had a METAVIR score F4 defined by fibroscan or liver biopsy 37. Therefore, the more advanced the liver fibrosis, the higher the risk of anemia, as already shown by other studies 38. However, given the current trend in reducing the use of RBV,39 the impact of this element will be further reduced.…”

Section: Discussionmentioning

confidence: 56%

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

Cenderello¹,

Fanizza²,

Marenco³

et al. 2017

CEOR

View full text Add to dashboard Cite

AimsDespite the remarkable efficacy shown in clinical practice, concerns have been raised about the costs associated with direct antiviral agent (DAA) therapy. This article presents the real-life costs for DAA treatment sustained by the Italian National Health Service in the Liguria Region (Northern Italy).MethodsA retrospective analysis of the cost per care sustained for DAA treatment, relating to the period from January 1 to December 31, 2015 in five centers in Liguria was performed. All patients undergoing DAA-based treatments for hepatitis C virus (HCV) infection were enrolled. On-treatment costs included: HCV treatment, laboratory test, outpatient services, attended visits, drugs used for the management of adverse events (erythropoietin, albumin or red blood cell packs) and inpatient service admissions.ResultsIn total, 327 patients were enrolled. No difference in terms of sustained virologic response (SVR) rate among different treatments was reported. The majority (85.0%) of patients did not report any side effects and only 15 (4.6%) required hospital admission. Forty-two patients (12.8%) required high-cost drugs for the management of adverse events. The overall cost sustained was €14,744,433. DAA±ribavirin (RBV) accounted for the wide majority of this cost (98.9%; €14,585,123). Genotype (GT) 1, the most commonly treated GT, was associated with an average cost of €43,445 per patient. Detailed analysis of the costs for GT 1 showed the treatment based on ritonavir boosted paritaprevir/ombitasvir + dasabuvir±RBV with an average cost of €24,978 (RBV+) and €25,448 (RBV−) per patient was the most cost-effective. The average cost per SVR was €48,184. Once again, the ritonavir boosted paritaprevir/ombitasvir + dasabuvir regimen was associated with the lowest cost/SVR (€25,448/SVR [GT 1b] and similar results for other GTs).ConclusionAntiviral regimen is the major contributor to costs in the treatment of HCV infection. Appropriate regimen selection could result in a major cost saving, which can be reinvested to allow more patients to be treated.

show abstract

“…Our results were in agreement with those of Mostafa et al . [ 21 ], who reported that the hematological side effects of PegINF/RBV regimens included anemia (30.6%) and leukopenia (9.8%) in Egyptian patients with HCV GT4 infection.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

Abdel-Moneim

Abood

Abdel-Gabaar

et al. 2018

ceh

View full text Add to dashboard Cite

IntroductionNew regimens involving direct-acting antiviral agents (DAAs) have recently been approved for the treatment of hepatitis C virus (HCV) genotype 4 (GT4). The current study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 patients at the beginning of the interferon-free era.Material and methodsBetween March 2015 and November 2015, 99 patients (59 naïve and 40 experienced) infected with HCV GT4 were enrolled in the study. Eligible patients received daily oral 400 mg SOF, RBV (body weight: < 75 kg, 1000 mg; < 75 kg, 1200 mg), the dose modified according to patient tolerability, plus 180 μg PegINFα-2 once weekly for 12 weeks.ResultsAmong the patient cohort, sustained virological response 12 weeks after the end of treatment (SVR12) was achieved by 88% (87/99) of all patients, by 93% (55/59) of naïve patients and by 80% (32/40) of experienced patients. Regarding treatment failure, the data recorded 12% (12/99) of patients (4 null responses and 8 relapsers). Otherwise, the most common adverse events observed during the study included headache, nausea, fatigue, dyspnea, influenza-like illness, anemia, and leukopenia.ConclusionsSOF combination-based therapies were considered promising choice regimens for chronic HCV infection. The present findings suggest that the combination of the SOF/PegINF/RBV regimen was effective for Egyptian patients with HCV GT4. The recorded adverse events and viral outcome revealed the high need for further efforts to minimize the side effects of the current regimen and/or replace PegINF with additional potent DAA(s) to increase SVR12 to achieve 100%.

show abstract

Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin

Abstract: Fibrosis stage and week 2 and 4 hematological parameter reduction levels were independent predictors of hematological side effects, which are not related to interferon type.

Cited by 8 publications

References 27 publications

تقييم الحالة الغذائية لمرضى الالتهاب الکبدي سي بمستشفى کبد المحلة التعليمي

تقييم الحالة الغذائية لمرضى الالتهاب الکبدي سي بمستشفى کبد المحلة التعليمي

Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

Contact Info

Product

Resources

About